## 1. Phylogeny

Tyrosine‐protein kinase Lck is a prototypical member of the Src family kinases (SFKs), a subgroup of non‐receptor tyrosine kinases that emerged in parallel with the evolution of the adaptive immune system among vertebrates. Lck is expressed almost exclusively in T-lineage cells, and its evolutionary conservation is underscored by its modular domain architecture that includes an N-terminal SH4 region, a unique regulatory domain, SH3 and SH2 domains, and a catalytic kinase (SH1) domain. Comparative sequence analyses strongly support the grouping of Lck with its closest relatives—Fyn, Src, Yes, and Lyn—which share key regulatory motifs responsible for intramolecular autoinhibition, as well as activation through conformational rearrangements that expose the catalytic cleft. Structural and phylogenetic studies demonstrate that the modular organization of Lck, with its N-terminal lipid modifications including myristoylation and palmitoylation, is highly conserved, suggesting that these features were critical for membrane targeting when the Src family originally evolved in vertebrates (bajaj2023crystalstructureof pages 1-2, kwon2019tracingtheevolution pages 1-10). In vertebrate species, orthologs of Lck have been identified predominantly in mammals. These orthologs retain not only the characteristic domain organization but also the regulatory phosphorylation sites that are essential for its function in TCR signaling. The restricted distribution of Lck to cells of the adaptive immune system reflects its specialized role in T-cell activation and thymocyte development, with evolutionary pressures having refined its regulatory mechanisms alongside the increasing complexity of vertebrate immune responses (bommhardt2019beyondtcrsignaling pages 9-11, elkamhawy2021newhorizonsin pages 1-3). Such evolutionary conservation from early vertebrates to modern mammals highlights the importance of Lck as part of the core signaling machinery that orchestrates T-cell receptor-mediated immune responses (mace2021there’smoreto pages 1-5).

## 2. Reaction Catalyzed

Lck catalyzes the phosphorylation reaction that is central to T-cell signal transduction. The enzyme transfers the γ-phosphate moiety from adenosine triphosphate (ATP) to the hydroxyl group of specific tyrosine residues on protein substrates. This catalytic process can be summarized by the general reaction:  
  ATP + protein–Tyr → ADP + protein–pTyr + H⁺.  
Within T cells, this reaction is particularly critical for the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) located on the cytoplasmic portions of the T-cell receptor (TCR) complex and CD3 subunits. Phosphorylation of ITAMs creates binding sites for downstream signaling proteins, in particular the SH2 domain-containing kinase ZAP70, which is then recruited and activated to further propagate the signal cascade that ultimately leads to lymphokine production and T-cell activation (bajaj2023crystalstructureof pages 1-2, bommhardt2019beyondtcrsignaling pages 9-11). In addition to its role in ITAM phosphorylation, Lck also phosphorylates other substrates that are involved in fine-tuning the immune response. These substrates include signaling adaptors and regulatory proteins such as RUNX3, PTK2B/PYK2, MAPT (microtubule-associated protein tau), RHOH, and TYROBP, which participate in diverse cellular processes ranging from transcriptional regulation to cytoskeletal rearrangements (sanctis2024lckfunctionand pages 24-25, zhang2023newinsightsinto pages 1-2). The reaction mechanism is thought to involve the coordination of ATP with a divalent metal ion—most commonly Mg²⁺—within a catalytic pocket that is optimized by critical amino acid residues, thereby lowering the activation barrier required for the phosphotransfer reaction. Furthermore, autophosphorylation of Lck at specific tyrosine residues within the activation loop, particularly on Y394, is essential for the full activation of the kinase and proper alignment of the catalytic residues (sanctis2024lckfunctionand pages 4-6, kwon2019tracingtheevolution pages 10-15).

## 3. Cofactor Requirements

The enzymatic activity of Lck is highly dependent on cofactors that assist in stabilizing both the substrate and the transition state during catalysis. Chief among these cofactors is the divalent metal ion magnesium (Mg²⁺), which plays a pivotal role by coordinating with the phosphate groups of ATP. This coordination not only stabilizes the negative charges present on the phosphate groups but also correctly positions the γ-phosphate for nucleophilic attack by the hydroxyl group of the target tyrosine residue (bajaj2023crystalstructureof pages 1-2, sanctis2024lckfunctionand pages 16-18). Although some biochemical assays have demonstrated that manganese (Mn²⁺) can partially substitute for Mg²⁺ under in vitro conditions, the physiological milieu predominantly favors Mg²⁺, which is essential for the proper mimicking of the intracellular environment. In addition to metal ions, the lipid modifications that occur at the N-terminus of Lck—namely myristoylation and palmitoylation—are crucial for its catalytic function. These modifications ensure that Lck is accurately targeted to the plasma membrane and partitioned into cholesterol-rich lipid rafts, which are microdomains where the T-cell receptor and its associated substrates are localized. This strategic localization is indispensable for the efficient transmission of the phosphorylation signal upon TCR engagement (bommhardt2019beyondtcrsignaling pages 9-11, elkamhawy2021newhorizonsin pages 1-3).

## 4. Substrate Specificity

Lck exhibits a high degree of substrate specificity that is governed by both its catalytic domain and its accessory SH2 and SH3 domains. The primary physiological substrates for Lck are components of the TCR-CD3 complex, particularly the ITAM sequences located on the intracellular domains of the TCR-gamma chains and CD3 subunits. Phosphorylation of these ITAMs is a key initiating event in T-cell activation, as it facilitates the recruitment of ZAP70 through its phosphotyrosine-binding SH2 domains (bajaj2023crystalstructureof pages 1-2, sanctis2024lckfunctionand pages 24-25). In addition to the TCR complex, Lck phosphorylates several other proteins that play important roles in T-cell signaling and cellular structural dynamics. Notable substrates include the transcription factor RUNX3, involved in T-cell differentiation; the focal adhesion kinase PTK2B/PYK2, which functions in cell migration and cytoskeletal reorganization; MAPT (microtubule-associated protein tau), which has implications in neuronal structure as well as cytoskeletal functions in T cells; the small GTPase RHOH, a modulator of T-cell receptor signaling; and the adaptor protein TYROBP, which has roles in immune receptor signaling (bommhardt2019beyondtcrsignaling pages 5-7, sanctis2024lckfunctionand pages 13-14). Moreover, Lck directly interacts with the cytoplasmic tail of CD2, a cell surface adhesion molecule, leading to hyperphosphorylation events that further augment its kinase activity. While the precise consensus sequence for Lck substrate phosphorylation remains under investigation, it generally demonstrates a preference for tyrosine residues located within a spatial context that allows optimal docking via its SH2 and SH3 domains. These docking interactions not only enhance substrate recognition but also contribute to the overall specificity of Lck (elkamhawy2021newhorizonsin pages 26-27, sanctis2024lckfunctionand pages 13-14, zhang2023newinsightsinto pages 1-2).

## 5. Structure

The structure of Lck, like other Src family kinases, is characterized by a modular organization that supports both its catalytic activity and its regulatory control. The N-terminal portion of Lck contains an SH4 domain that undergoes myristoylation at a glycine residue (typically at position 2) and palmitoylation at one or more cysteine residues. These post-translational modifications are critical determinants for the membrane localization of Lck, thereby targeting it to lipid rafts—cholesterol-rich microdomains that serve as hubs for signal transduction in T cells (bajaj2023crystalstructureof pages 1-2, rocka2024pathwayoflck pages 2-4). Immediately following the SH4 domain is the unique domain (UD), which, although less conserved in sequence among SFKs, confers family-specific regulatory properties and facilitates interactions with T-cell coreceptors such as CD4 and CD8. This domain often serves as a flexible linker that accommodates conformational changes necessary during the transition between inactive and active states.

Downstream of the unique domain are the SH3 and SH2 domains. The SH3 domain of Lck recognizes and binds to proline-rich motifs, and it contributes to an autoinhibitory conformation by interacting with a proline-rich segment located in the interdomain linker when the kinase is inactive. The SH2 domain, on the other hand, binds specifically to phosphotyrosine-containing sequences; this characteristic not only ensures that Lck remains properly positioned within signaling complexes but also plays a role in maintaining a closed conformation when phosphorylated at key regulatory tyrosine residues (sanctis2024lckfunctionand pages 2-4, mace2021there’smoreto pages 1-5).

The catalytic domain (SH1 domain) occupies the C-terminal region of Lck and is the engine of its enzymatic activity. This domain adopts a canonical bilobed structure composed of an N-terminal lobe enriched in β-sheets and a C-terminal lobe predominantly made up of α-helices. Within this catalytic core, several conserved residues are essential: a lysine residue in the β3-strand is critical for binding ATP, while a glutamic acid in the αC-helix forms a salt bridge with the lysine to correctly position ATP for catalysis. The activation loop in the catalytic domain, containing the critical tyrosine Y394, undergoes conformational changes upon phosphorylation, thereby switching Lck from an inactive, closed state to an open, catalytically competent conformation (bajaj2023crystalstructureof pages 1-2, sanctis2024lckfunctionand pages 4-6, elkamhawy2021newhorizonsin pages 26-27). In contrast, phosphorylation of Y505 in the C-terminal tail produces an intramolecular interaction wherein the phosphorylated tail docks into the SH2 domain, generating an autoinhibited, closed structure (sanctis2024lckfunctionand pages 4-6). High-resolution X-ray crystallography data and AlphaFold2 structural predictions have corroborated these conformational states and provided a detailed glimpse of the dynamic nature of the kinase domain, highlighting the flexibility of the activation loop that is essential for substrate binding and catalysis (faezov2023alphafold2modelsof pages 1-4).

## 6. Regulation

The activity of Lck is intricately regulated by multiple post-translational modifications and protein–protein interactions that ensure signaling fidelity during T-cell activation. Central to the regulation of Lck are the phosphorylation events that occur at two critical tyrosine residues: Y394 and Y505. In its inactive state, Lck is phosphorylated at Y505 by the C-terminal Src kinase (Csk), which promotes the binding of the phosphorylated tail to the SH2 domain, thereby locking the kinase in a closed conformation that is catalytically inert (sanctis2024lckfunctionand pages 4-6, bommhardt2019beyondtcrsignaling pages 9-11). Upon engagement of the T-cell receptor by a peptide-MHC complex, the transmembrane phosphatase CD45 is activated and dephosphorylates Y505, releasing the inhibitory interaction and permitting the autophosphorylation of Y394. Phosphorylation at Y394 stabilizes an open, active conformation which is essential for efficient substrate phosphorylation and signal propagation (bajaj2023crystalstructureof pages 1-2, sanctis2024lckfunctionand pages 18-20).

Further refinement of Lck’s activity involves the phosphorylation of Y192 located in the SH2 domain. Phosphorylation at this site has been shown to diminish the regulatory influence of CD45 by interfering with its dephosphorylating capacity, thereby contributing to the fine-tuning of kinase activity (sanctis2024lckfunctionand pages 13-14, kwon2019tracingtheevolution pages 10-15). Moreover, the intramolecular interactions between the SH3 and SH2 domains facilitate additional layers of autoregulation. In the closed conformation, these interactions further secure Lck in its inactive state. Conversely, during T-cell activation, these interactions are disrupted, contributing to the transition toward the open, active conformation (bommhardt2019beyondtcrsignaling pages 9-11, sanctis2024lckfunctionand pages 20-21).

Regulation of Lck is also critically influenced by its lipid modifications. The myristoylation and palmitoylation at the SH4 domain are indispensable for targeting Lck to the plasma membrane and for its partitioning into lipid rafts, where the key components of the TCR signaling complex reside. This membrane association not only brings Lck into proximity with its substrates but also impacts its dynamic regulatory interactions with other proteins, such as the CD4 and CD8 coreceptors (elkamhawy2021newhorizonsin pages 1-3, sanctis2024lckfunctionand pages 16-18). In addition, Lck activity can be modulated via interactions with other receptor systems such as CD2 and the IL2 receptor. In CD2 signaling, for instance, the direct association with the cytoplasmic tail of CD2 enhances Lck phosphorylation and activity, whereas IL2 receptor engagement results in further amplification of kinase activity, thereby supporting T-cell proliferation (bommhardt2019beyondtcrsignaling pages 5-7, sanctis2024lckfunctionand pages 24-25).  
Together, these layers of regulation—including reversible phosphorylation, lipid modification for subcellular localization, and protein–protein interactions—provide a tightly controlled mechanism to ensure that Lck is activated only under appropriate immunological contexts, thereby preventing aberrant signaling that could lead to autoimmunity or oncogenesis (kwon2019tracingtheevolution pages 32-37, sanctis2024lckfunctionand pages 20-21).

## 7. Function

Lck serves as a central signaling hub in T cells and plays an indispensable role in the development, activation, and proliferation of these cells. Expressed at all stages of thymocyte maturation, Lck is critical for both positive and negative selection in the thymus, thus shaping the functional T-cell repertoire (sanctis2024lckfunctionand pages 1-2). Upon antigen recognition, the T-cell receptor (TCR) is engaged with peptide-MHC complexes. Due to the constitutive association of Lck with the cytoplasmic tails of the CD4 and CD8 coreceptors, Lck is recruited to the vicinity of the TCR-CD3 complex, where it phosphorylates ITAM motifs on TCR-gamma chains and CD3 subunits (bajaj2023crystalstructureof pages 1-2, sanctis2024lckfunctionand pages 24-25). This event is critical both for the subsequent recruitment of ZAP70, via the SH2 domain of ZAP70 binding to these phosphorylated sites, and for the initiation of a cascade of downstream signaling events that drive T-cell activation, lymphokine production, and clonal expansion (bommhardt2019beyondtcrsignaling pages 9-11).

Beyond its fundamental role in TCR signaling, Lck phosphorylates a range of other substrates that extend its functional repertoire within T cells. These substrates include the transcription factor RUNX3, which is involved in regulating gene expression during T-cell differentiation; PTK2B/PYK2, a focal adhesion kinase implicated in cell motility and adhesion; MAPT, the microtubule-associated protein tau, which contributes to cytoskeletal organization; RHOH, a small GTPase that modulates the dynamics of receptor signaling; and TYROBP, an adaptor protein associated with immune receptor complexes (bommhardt2019beyondtcrsignaling pages 1-3, sanctis2024lckfunctionand pages 13-14). In addition, Lck is known to interact directly with the cytoplasmic tail of CD2, leading to hyperphosphorylation events that further enhance its signaling capacity. Within the context of interleukin-2 (IL2) receptor signaling, binding of IL2 leads to an upregulation of Lck activity, which in turn supports T-cell proliferation and survival, underscoring its role in mediating signals that govern immune homeostasis (elkamhawy2021newhorizonsin pages 29-30, sanctis2024lckfunctionand pages 24-25).

Thus, Lck functions as a key signal integrator, ensuring that signals emanating from different receptor systems—including the TCR, CD2, and IL2 receptor—are appropriately coordinated to yield a robust and finely tuned T-cell response. This integration is vital not only for the initiation of immune responses but also for the maintenance of immune tolerance, as both hyperactivation and insufficient activation of Lck can lead to pathological conditions such as autoimmune diseases or T-cell malignancies (bommhardt2019beyondtcrsignaling pages 9-11, sanctis2024lckfunctionand pages 4-6).

## 8. Other Comments

Because of its central role in T-cell receptor signaling and immune activation, Lck has been recognized as a promising therapeutic target in a range of disease contexts. Aberrant Lck activity has been associated with autoimmune disorders, where inappropriate activation can lead to self-reactive T cells, as well as with hematologic malignancies such as T-cell leukemias, in which hyperactive Lck signaling supports uncontrolled cell proliferation and survival (sanctis2024lckfunctionand pages 13-14, sanctis2024lckfunctionand pages 18-20). Small-molecule inhibitors that target Lck—either directly or as part of the broader class of Src family kinase inhibitors—have been explored in both preclinical and clinical settings. Examples include the use of dasatinib and PP2, which, despite their lack of complete specificity for Lck, have provided proof-of-concept evidence that pharmacological modulation of Lck can alter T-cell signaling outcomes (bommhardt2019beyondtcrsignaling pages 9-11, sanctis2024lckfunctionand pages 24-25). Ongoing research efforts are focused on the development of more selective inhibitors that specifically target the unique regulatory domains of Lck, including approaches that exploit allosteric binding sites rather than the highly conserved ATP-binding pocket. These novel strategies seek to minimize off-target effects and improve therapeutic outcomes, particularly in the context of adoptive cell therapies such as CAR T-cell treatments, where fine-tuning Lck activity could enhance antitumor efficacy while reducing the risk of T-cell exhaustion (jha2025deeplearningcoupledproximity pages 20-22).

New insights into the role of lipid modifications in regulating Lck function have also emerged. The balance between myristoylation and palmitoylation not only determines Lck’s membrane localization but also affects its interactions with other signaling molecules in lipid rafts. Variations in membrane cholesterol levels, as well as the activity of specific palmitoyl transferases, have been shown to modulate the spatial distribution of Lck and consequently influence T-cell activation thresholds (sanctis2024lckfunctionand pages 2-4, elkamhawy2021newhorizonsin pages 1-3).

Moreover, hyperphosphorylation of Y394 or persistent inhibitory phosphorylation at Y505 has been observed in specific pathological conditions, suggesting that precise modulation of these key regulatory residues may offer an avenue for therapeutic intervention. Detailed investigations using structural and biophysical approaches, including crystallography and advanced computational modeling via AlphaFold2, continue to elucidate the dynamic conformational landscape of Lck and inform structure-guided drug design efforts (faezov2023alphafold2modelsof pages 1-4, sanctis2024lckfunctionand pages 4-6).

In summary, Lck is not only pivotal for T-cell receptor signaling but is also a critical node in immune regulation and tumor immunology. Its complex regulatory network, comprising both post-translational modifications and protein–protein interactions, provides multiple potential therapeutic targets for modulating immune responses. As research advances, improved understanding of these regulatory mechanisms will be essential for developing next-generation inhibitors with the specificity and potency necessary for clinical application (bommhardt2019beyondtcrsignaling pages 9-11, sanctis2024lckfunctionand pages 24-25).

## 9. References

bajaj2023crystalstructureof pages 1-2; bajaj2023crystalstructureof pages 5-7; bommhardt2019beyondtcrsignaling pages 1-3; bommhardt2019beyondtcrsignaling pages 5-7; bommhardt2019beyondtcrsignaling pages 7-9; bommhardt2019beyondtcrsignaling pages 9-11; elkamhawy2021newhorizonsin pages 1-3; elkamhawy2021newhorizonsin pages 23-26; elkamhawy2021newhorizonsin pages 26-27; elkamhawy2021newhorizonsin pages 29-30; elkamhawy2021newhorizonsin pages 3-5; faezov2023alphafold2modelsof pages 1-4; jha2025deeplearningcoupledproximity pages 20-22; kwon2019tracingtheevolution pages 1-10; kwon2019tracingtheevolution pages 10-15; kwon2019tracingtheevolution pages 32-37; mace2021there’smoreto pages 1-5; rocka2024pathwayoflck pages 2-4; sanctis2024lckfunctionand pages 1-2; sanctis2024lckfunctionand pages 4-6; sanctis2024lckfunctionand pages 6-8; sanctis2024lckfunctionand pages 8-10; sanctis2024lckfunctionand pages 10-13; sanctis2024lckfunctionand pages 13-14; sanctis2024lckfunctionand pages 14-16; sanctis2024lckfunctionand pages 16-18; sanctis2024lckfunctionand pages 18-20; sanctis2024lckfunctionand pages 20-21; sanctis2024lckfunctionand pages 21-22; sanctis2024lckfunctionand pages 24-25; zhang2023newinsightsinto pages 1-2.

References

1. (bajaj2023crystalstructureof pages 1-2): Teena Bajaj, John Kuriyan, and Christine L. Gee. Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, monosiga brevicollis. PLOS ONE, 18:e0276413, Jun 2023. URL: https://doi.org/10.1371/journal.pone.0276413, doi:10.1371/journal.pone.0276413. This article has 5 citations and is from a peer-reviewed journal.
2. (bajaj2023crystalstructureof pages 5-7): Teena Bajaj, John Kuriyan, and Christine L. Gee. Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, monosiga brevicollis. PLOS ONE, 18:e0276413, Jun 2023. URL: https://doi.org/10.1371/journal.pone.0276413, doi:10.1371/journal.pone.0276413. This article has 5 citations and is from a peer-reviewed journal.
3. (bommhardt2019beyondtcrsignaling pages 1-3): Ursula Bommhardt, Burkhart Schraven, and Luca Simeoni. Beyond tcr signaling: emerging functions of lck in cancer and immunotherapy. International Journal of Molecular Sciences, 20:3500, Jul 2019. URL: https://doi.org/10.3390/ijms20143500, doi:10.3390/ijms20143500. This article has 150 citations and is from a peer-reviewed journal.
4. (bommhardt2019beyondtcrsignaling pages 5-7): Ursula Bommhardt, Burkhart Schraven, and Luca Simeoni. Beyond tcr signaling: emerging functions of lck in cancer and immunotherapy. International Journal of Molecular Sciences, 20:3500, Jul 2019. URL: https://doi.org/10.3390/ijms20143500, doi:10.3390/ijms20143500. This article has 150 citations and is from a peer-reviewed journal.
5. (bommhardt2019beyondtcrsignaling pages 7-9): Ursula Bommhardt, Burkhart Schraven, and Luca Simeoni. Beyond tcr signaling: emerging functions of lck in cancer and immunotherapy. International Journal of Molecular Sciences, 20:3500, Jul 2019. URL: https://doi.org/10.3390/ijms20143500, doi:10.3390/ijms20143500. This article has 150 citations and is from a peer-reviewed journal.
6. (bommhardt2019beyondtcrsignaling pages 9-11): Ursula Bommhardt, Burkhart Schraven, and Luca Simeoni. Beyond tcr signaling: emerging functions of lck in cancer and immunotherapy. International Journal of Molecular Sciences, 20:3500, Jul 2019. URL: https://doi.org/10.3390/ijms20143500, doi:10.3390/ijms20143500. This article has 150 citations and is from a peer-reviewed journal.
7. (elkamhawy2021newhorizonsin pages 1-3): Ahmed Elkamhawy, Eslam M. H. Ali, and Kyeong Lee. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (sar) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1572-1600, Jan 2021. URL: https://doi.org/10.1080/14756366.2021.1937143, doi:10.1080/14756366.2021.1937143. This article has 25 citations and is from a peer-reviewed journal.
8. (elkamhawy2021newhorizonsin pages 23-26): Ahmed Elkamhawy, Eslam M. H. Ali, and Kyeong Lee. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (sar) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1572-1600, Jan 2021. URL: https://doi.org/10.1080/14756366.2021.1937143, doi:10.1080/14756366.2021.1937143. This article has 25 citations and is from a peer-reviewed journal.
9. (elkamhawy2021newhorizonsin pages 26-27): Ahmed Elkamhawy, Eslam M. H. Ali, and Kyeong Lee. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (sar) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1572-1600, Jan 2021. URL: https://doi.org/10.1080/14756366.2021.1937143, doi:10.1080/14756366.2021.1937143. This article has 25 citations and is from a peer-reviewed journal.
10. (elkamhawy2021newhorizonsin pages 29-30): Ahmed Elkamhawy, Eslam M. H. Ali, and Kyeong Lee. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (sar) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1572-1600, Jan 2021. URL: https://doi.org/10.1080/14756366.2021.1937143, doi:10.1080/14756366.2021.1937143. This article has 25 citations and is from a peer-reviewed journal.
11. (elkamhawy2021newhorizonsin pages 3-5): Ahmed Elkamhawy, Eslam M. H. Ali, and Kyeong Lee. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (sar) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36:1572-1600, Jan 2021. URL: https://doi.org/10.1080/14756366.2021.1937143, doi:10.1080/14756366.2021.1937143. This article has 25 citations and is from a peer-reviewed journal.
12. (faezov2023alphafold2modelsof pages 1-4): Bulat Faezov and Roland L. Dunbrack. Alphafold2 models of the active form of all 437 catalytically competent human protein kinase domains. BioRxiv, Jul 2023. URL: https://doi.org/10.1101/2023.07.21.550125, doi:10.1101/2023.07.21.550125. This article has 28 citations.
13. (jha2025deeplearningcoupledproximity pages 20-22): Kanchan Jha, Daichi Shonai, Aditya Parekh, Akiyoshi Uezu, Tomoyuki Fujiyama, Hikari Yamamoto, Pooja Parameswaran, Masashi Yanagisawa, Rohit Singh, and Scott H. Soderling. Deep learning-coupled proximity proteomics to deconvolve kinase signaling in vivo. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.27.650849, doi:10.1101/2025.04.27.650849. This article has 0 citations.
14. (kwon2019tracingtheevolution pages 1-10): HA Kwon. Tracing the evolution of the tyrosine kinome from sequence to function. Unknown journal, 2019.
15. (kwon2019tracingtheevolution pages 10-15): HA Kwon. Tracing the evolution of the tyrosine kinome from sequence to function. Unknown journal, 2019.
16. (kwon2019tracingtheevolution pages 32-37): HA Kwon. Tracing the evolution of the tyrosine kinome from sequence to function. Unknown journal, 2019.
17. (mace2021there’smoreto pages 1-5): Peter D. Mace and James M. Murphy. There’s more to death than life: noncatalytic functions in kinase and pseudokinase signaling. The Journal of Biological Chemistry, Apr 2021. URL: https://doi.org/10.1016/j.jbc.2021.100705, doi:10.1016/j.jbc.2021.100705. This article has 76 citations.
18. (rocka2024pathwayoflck pages 2-4): Agata Rocka, Maria Suchcicka, Aleksandra Jankowska, Magdalena Woźniak, and Monika Lejman. Pathway of lck tyrosine kinase and mtor signaling in children with t-cell acute lymphoblastic leukemia. The Application of Clinical Genetics, Volume 17:187-198, Nov 2024. URL: https://doi.org/10.2147/tacg.s494389, doi:10.2147/tacg.s494389. This article has 0 citations.
19. (sanctis2024lckfunctionand pages 1-2): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
20. (sanctis2024lckfunctionand pages 10-13): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
21. (sanctis2024lckfunctionand pages 13-14): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
22. (sanctis2024lckfunctionand pages 14-16): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
23. (sanctis2024lckfunctionand pages 16-18): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
24. (sanctis2024lckfunctionand pages 18-20): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
25. (sanctis2024lckfunctionand pages 2-4): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
26. (sanctis2024lckfunctionand pages 20-21): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
27. (sanctis2024lckfunctionand pages 21-22): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
28. (sanctis2024lckfunctionand pages 24-25): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
29. (sanctis2024lckfunctionand pages 4-6): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
30. (sanctis2024lckfunctionand pages 6-8): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
31. (sanctis2024lckfunctionand pages 8-10): Juan De Sanctis, Jenny Garmendia, Hana Duchová, Viktor Valentini, Alex Puskasu, Agáta Kubíčková, and Marián Hajdúch. Lck function and modulation: immune cytotoxic response and tumor treatment more than a simple event. Cancers, 16:2630, Jul 2024. URL: https://doi.org/10.3390/cancers16152630, doi:10.3390/cancers16152630. This article has 3 citations and is from a peer-reviewed journal.
32. (zhang2023newinsightsinto pages 1-2): Jing Zhang, Yu-Jing Wu, Xiao-Xi Hu, and Wei Wei. New insights into the lck-nf-κb signaling pathway. Frontiers in Cell and Developmental Biology, Feb 2023. URL: https://doi.org/10.3389/fcell.2023.1120747, doi:10.3389/fcell.2023.1120747. This article has 9 citations and is from a peer-reviewed journal.